Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Regional Health Authorities to Meet and Discuss Russia’s 2020 Vision

Published: Thursday, September 05, 2013
Last Updated: Thursday, September 05, 2013
Bookmark and Share
Government aims for 50% of sold drugs to be manufactured in Russia by 2020.

The Russian pharmaceutical market is one of the fastest growing in the world. Its value is predicted to rise from $24 billion in 2012 to $75 billion by 2020, according to Cegedim Relationship Management’s aggregated opinion from industry experts, government employees and analysts.

The pharma 2020 strategy proposed by the government, which aims for 50% of sold drugs to be manufactured in Russia by 2020 – has encouraged many multinational organizations to locate manufacturing in Russia. However, there are some crucial structural defects in this market, such as complex administrative procedures and insufficient international cooperation, which tend to inhibit its full development. Foreign companies continue to face challenges surrounding government regulations and unclear requirements to achieve GMP, while local manufacturers grapple with limited capabilities and technical know-how.

In an effort to take Russia a step closer towards achieving its 2020 pharma vision, representatives from the Ministry of Ukraine, RIBS Kazakhstan, and other regional health authorities will gather on 7-8 November 2013 at Vaccine World CIS and CEE 2013 to help local manufacturers by equipping them with the required technical know-how, and helping them overcome challenges relating to manufacturing and R&D, and regulatory controls. International players will also have the chance to meet and build relationships/ forge partnerships with local manufacturers.

Over 25 vaccine industry experts will come together to share information on topics like the vaccine market overview, Russia’s 2020 vision, innovative approaches and best practices to vaccine manufacturing, manufacturing excellence and quality assurance, next generation vaccine development, vaccine technology, and partnerships.

The list of speakers and advisors that will participating at this gathering include:

•    Kim Bush, Director, Life Sciences Partnerships, Global Health Program, Bill & Melinda Gates Foundation
•    Dr. Yurii Gamazin, Senior Advisor to the Director General, Ukrainian State Expert Center, Ukraine
•    Natalia Puchkova, First Deputy General Director, Petrovax Pharm, Russia
•    Berik Khairullin, Deputy General Director, RIBS, Kazakhstan
•    Ugo D’Oro, Head of Unit in the Immunology Function, Novartis Vaccines Research, Italy
•    Alexander Ivanov, Research Scientist, Microgen Holding
•    iviana Teresa Sara Gianninò, Researcher and Project Leader, Etna Biotech s.r.l., Catania – Zydus Cadila Research Center (Cadila Healthcare, Ahmedabad - India)
•    Peter Keller, Chief Business Officer, Selecta Biosciences
•    S.D. Ravetkar, Executive Director, Serum Institute of India Ltd, India
•    Werner Cautreels, CEO, Selecta Biosciences, USA
•    Nikolai Petrovsky, Chairman, Vaxine, Australia
•    Sergey Dudkin, Director, Strategy and Development, NewVac LLC, Russia
•    Jiri Hermanek, CEO, Sotio, Russia
•    Sayadyan Khachik, CEO, ABIOLEK & Chief of Science and Development, NT Pharma, Russia
•    Jeffrey Ulmer, Global Head, External Research Novartis, USA
•    Boro Dropulic, President and Chief Scientific Officer, Lentigen Corporation, USA
•    Kateryna Gamazina, Country Director, PATH
•    Igor Orshanskiy, CEO, NewVac, Russia


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

IMAPAC to Bring Together Over 150 Leading Industry Players
IMAPAC’s 3rd Biologics Korea gathering from 22-24 April 2014 in Seoul, Korea.
Wednesday, February 19, 2014
Top Biologic Industry Leaders to Convene at Biologics World Korea 2013
Bringing together biologics drug innovators and bioprocess professionals from all around the world to discuss strategies in biosimilar and biobetter development, as well as cutting-edge advances in bioprocessing and bioanalytics.
Friday, December 07, 2012
Last Days of the Early Bird Pricings for Biologics World China 2012
Keep up to date with China’s changing biopharma landscape by registering for Biologics World China 2012.
Monday, September 24, 2012
The Movement of China's Burgeoning Biologics Market
Facilitate innovation and manufacturing of affordable and high quality biologic drugs and vaccines in China.
Friday, August 24, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Monkeys Protected by Zika DNA Vaccine
Experimental Zika virus DNA vaccines successfully protected monkeys against Zika infection.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!